Localized Prostate Cancer VL

NCCN Prostate Cancer Clinical Practice Guidelines on Risk Stratification for Clinically Localized Prostate Cancer – Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club presentation Christopher Wallis and Zachary Klaassen, continue their in-depth review of the NCCN clinical practice guidelines in prostate cancer focusing on risk stratification for clinically localized disease. They focus on risk stratification for patients with prostate cancer. Dr. Christopher Wallis discusses the use of nomograms and the use of Tumor Multigene Molec...

Improving the Quality of Care for Men in Michigan With Prostate Cancer, the MUSIC Collaborative, a Focus on the G-MINOR and G-MAJOR Trials – Todd Morgan

Details
In this conversation, Todd Morgan joins Mathew Cooperberg highlighting the success and current initiatives of the Michigan Urological Surgery Improvement Collaborative (MUSIC), program. MUSIC is an initiative started in 2012 by Drs. David Miller and Jim Montie in an effort to continuously improve the quality of care for men in Michigan with prostate cancer, MUSIC developed a systematic approach, o...

Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra

Details
In this UroToday presentation Daniel Spratt, MD, and Alan Dal Pra, MD, share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone therapy with postoperative radiation therapy and the clinical implications for Decipher. Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer C...

When to Add ADT to Early or Late Salvage Radiation - Dan Spratt

Details
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the RTOG...

Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt

Details
Ashley Ross, MD, PhD, Alan Dal Pra, MD, and Daniel Spratt, MD, discuss two cases of patients each about 18 months post-prostatectomy with rising PSA, evaluating the timing to radiotherapy and the evidence to intensify with ADT. Biographies: Ashley Ross, MD, Ph.D., Associate Professor, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois Alan Dal Pra, MD, A...

Prostate Cancer Screening and Shared Decision Making in the Veterans Health Administration - Stacy Loeb

Details
In this conversation, Mathew Cooperberg and Stacy Loeb discuss recent advances in prostate cancer screening and shared decision making in the Veterans Health Administration (VA). Dr. Loeb highlights findings from a Journal of the National Cancer Institute publication looking at trends of PSA screening in the VA healthcare system and which found a decline in the use of PSA testing among PSA eligibl...

PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu

Details
M Minhaj Siddiqui joins Matthew Cooperberg to highlight the Patient-Centered Outcomes Research Institute (PCORI) grant awarded to researchers at the University of Maryland School of Medicine (UMSOM). The grant supports the initiative to highlight, to a greater extent, the patient's voice in determining the next course of action to chart in the future of active surveillance in the United States. Mo...

Prostate Cancer Modeling: The CISNET Prostate Group - Ruth Etzioni

Details
Ruth Etzioni, PhD joins Matthew Cooperberg, MD MPH in a discussion about the role and history of prostate cancer modeling based upon PSA. Cancer Intervention and Surveillance Modeling Network (CISNET) is a consortium of NCI-sponsored investigators who use simulation modeling to improve our understanding of cancer control interventions in prevention, screening, and treatment and their effects on po...

Relugolix vs. Traditional ADT: A Comparative Analysis in the Setting of Definitive Therapy for Localized Disease - Ashley Ross

Details
Alicia Morgans and Ashley Ross delve into the use of relugolix in radiation settings for prostate cancer. They explore the drug's advantages, including rapid testosterone recovery and fewer cardiovascular side effects, making it a viable option for patients with intermediate to high-risk localized disease. Dr. Ross emphasizes the drug's utility in the "early salvage space," particularly for patien...

A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt

Details
Ashley Ross is joined by Daniel Spratt presenting a European Association of Urology publication on A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer . In a field of rapidly acquiring data, among the challenges that motivated this systematic review was the breadth of papers and data being published. Dr. Spratt and colleagues sought to acquire the most up-to-...